Oxcarbazepine — $0 on Listed Strengths

Other medications in Neurological

• Perampanel
• Phenobarbital
• Ponesimod
• Pramipexole
• Promethazine
• Propranolol
• Rasagiline
• Riluzole

About Oxcarbazepine

Oxcarbazepine is a vital medication prescribed to manage certain types of seizures in individuals with epilepsy. Understanding your treatment options and how to afford them is crucial. With TheDrugClub, you can access significant savings on prescriptions like oxcarbazepine, helping you maintain your health without breaking the bank.

Oxcarbazepine is primarily prescribed to control partial seizures (also known as focal seizures) in adults and children. These seizures originate in a specific area of the brain. It can be used alone or in combination with other anti-seizure medications. For many living with epilepsy, oxcarbazepine offers a crucial tool in managing their condition, helping to reduce the frequency and severity of seizures and improve overall quality of life.

At its core, oxcarbazepine works by stabilizing electrical activity in the brain. It's thought to achieve this by blocking voltage-sensitive sodium channels in nerve cells. By doing so, it reduces the abnormal firing of nerves that can lead to seizures. This action helps to prevent the spread of seizure

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Oxcarbazepine is approved for (FDA label)

Oxcarbazepine tablets is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. Oxcarbazepine tablets is indicated for: Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4–16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2–16 years ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 26, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Oxcarbazepine (FDA label)

Film-coated Tablets: 150 mg: pale yellow to brownish light green, oval shaped, film coated tablets, scored (functionally scored) on both sides and debossed with “OX 150ʼʼ on one side. 300 mg: light yellow to yellow, oval shaped, film coated tablets, scored (functionally scored) on both sides and debossed with ʽʽOX 300ʼʼ on one side. 600 mg: light Pink to Pink, oval shaped, film coated tablets, scored (functionally scored) on both sides and debossed with ʽʽOX 600ʼʼ on one side. Film-coated tablets: 150 mg, 300 mg and 600 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 8841174a-9f4b-424f-a50d-01478f2aeb29. SPL document ID: 372b49f4-e5ec-491f-9312-38dc0c5b63c6. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Oxcarbazepine (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: Hyponatremia [see Warnings and Precautions (5.1) ] Anaphylactic Reactions and Angioedema [see Warnings and Precautions (5.2) ] Cross Hypersensitivity Reaction to Carbamazepine [see Warnings and Precautions (5.3) ] Serious Dermatological Reactions [see Warnings and Precautions (5.4) ] Suicidal Behavior and Ideation [see Warnings and Precautions (5.5) ] Cognitive/Neuropsychiatric Adverse Reactions [see Warnings and Precautions (5.7) ] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multi-Organ Hypersensitivity [see Warnings and Precautions (5.8) ] Hematologic Events [see Warnings and Precautions (5.9) ] The most common (≥ 10% more than placebo for adjunctive or low dose for monotherapy) adverse reactions in adults and pediatrics were: dizziness, somnolence, diplopia, fatigue, nausea, vomiting, ataxia, abnormal vision, headache, nystagmus, tremor, and abnormal gait (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Zameer Pharmaceuticals LLC at 1-888-851-7033 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Most Common Adverse Reactions in All Clinical Studies Adjunctive Therapy/Monotherapy in Adults Previously Treated With Other AEDs The most common (≥ 10% more than placebo for adjunctive or low dose for monotherapy) adverse reactions with oxcarbazepine tablets: dizziness, somnolence, diplopia, fatigue, nausea, vomiting, ataxia, abnormal vision, headache, nystagmus tremor, and abnormal gait.

Source: FDA prescribing information (DailyMed). Set ID: 8841174a-9f4b-424f-a50d-01478f2aeb29. SPL document ID: 372b49f4-e5ec-491f-9312-38dc0c5b63c6. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Oxcarbazepine (FDA label)

Oxcarbazepine tablets is contraindicated in patients with a known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate [see Warnings and Precautions ( 5.2 , 5.3 )] . Known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate ( 4 , 5.2 )

Source: FDA prescribing information (DailyMed). Set ID: 8841174a-9f4b-424f-a50d-01478f2aeb29. SPL document ID: 372b49f4-e5ec-491f-9312-38dc0c5b63c6. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Oxcarbazepine (FDA label)

Hyponatremia: Monitor serum sodium levels ( 5.1 ) Cross Hypersensitivity Reaction to Carbamazepine: Discontinue immediately if hypersensitivity occurs ( 5.3 ) Serious Dermatological Reactions: If occurs, consider discontinuation ( 5.4 ) Suicidal Behavior and Ideation: Monitor for suicidal thoughts/behavior ( 5.5 ) Withdrawal of AEDs: Withdraw oxcarbazepine tablets gradually ( 5.6 ) Cognitive/Neuropsychiatric Adverse Reactions: May cause cognitive dysfunction, somnolence, and coordination abnormalities. Use caution when operating machinery ( 5.7 ) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multi-Organ Hypersensitivity: Monitor and discontinue if another cause cannot be established ( 5.8 ) Hematologic Events: Consider discontinuing ( 5.9 ) Seizure Control During Pregnancy: Active metabolite may decrease ( 5.10 ) Risk of Seizure Aggravation: Discontinue if occurs ( 5.11 ) 5.1 Hyponatremia Clinically significant hyponatremia (sodium < 125 mmol/L) can develop during oxcarbazepine tablets use.

Source: FDA prescribing information (DailyMed). Set ID: 8841174a-9f4b-424f-a50d-01478f2aeb29. SPL document ID: 372b49f4-e5ec-491f-9312-38dc0c5b63c6. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Oxcarbazepine (FDA label)

Phenytoin: Increased phenytoin levels. Reduced dose of phenytoin may be required ( 7.1 ) Carbamazepine, Phenytoin, and Phenobarbital: Decreased plasma levels of MHD (the active metabolite). Dose adjustments may be necessary ( 7.1 ) Oral Contraceptive: Oxcarbazepine tablets may decrease the effectiveness of hormonal contraceptives ( 7.3 ) 7.1 Effect of oxcarbazepine tablets on Other Drugs Phenytoin levels have been shown to increase with concomitant use of oxcarbazepine tablets at doses greater than 1200 mg/day [see Clinical Pharmacology (12.3) ] . Therefore, it is recommended that the plasma levels of phenytoin be monitored during the period of oxcarbazepine tablets titration and dosage modification.

Source: FDA prescribing information (DailyMed). Set ID: 8841174a-9f4b-424f-a50d-01478f2aeb29. SPL document ID: 372b49f4-e5ec-491f-9312-38dc0c5b63c6. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.